Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Bull Exp Biol Med ; 172(4): 441-446, 2022 Feb.
Article in English | MEDLINE | ID: mdl-35175471

ABSTRACT

Deposition of beta-amyloid peptide in the brain observed in Alzheimer's disease contributes to the development of cognitive deficits. We studied the abilities of different neuroprotectors to prevent or reduce degeneration of hippocampal neurons in rat brain 14 and 45 days after single intrahippocampal injection of beta-amyloid peptide 25-35 (Aß25-35). Cytological analysis of the neurons of the hippocampal CA1 and CA3 fields showed predominant damage to CA1 neurons in 14 days and CA3 neurons in 45 days after Aß25-35 administration. Single preliminary administrations of neuroprotectors fullerene C60FWS (antioxidant), neuromedin (nonselective inhibitor of acetylcholinesterase), and AM404 (activator of the endocannabinoid system) largely prevented neurodegeneration of neurons. Fullerene produced the most pronounced protective effect, which can be explained by its ability to prevent aggregation of proteins and destroy Aß25-35 fibrils. The combined use of these neuroprotectors can provide the basis for the development of new approaches to prevention and treatment of Alzheimer's disease.


Subject(s)
Acetylcholinesterase , Amyloid beta-Peptides , Acetylcholinesterase/metabolism , Amyloid beta-Peptides/metabolism , Animals , Hippocampus/metabolism , Neurons/metabolism , Peptide Fragments/pharmacology , Rats
2.
Bull Exp Biol Med ; 171(3): 327-332, 2021 Jul.
Article in English | MEDLINE | ID: mdl-34297297

ABSTRACT

We studied the prolonged action of kainic acid on glutamatergic neurons in the dorsal hippocampus and the endocannabinoid-dependent protection against neurodegeneration. The pyramidal neurons of the CA3 field of the hippocampus, as well as granular and mossy cells of the dentate gyrus were examined. Light and electron microscopy revealed substantial damage to the components of the protein-synthesizing (rough endoplasmic reticulum, Golgi apparatus, and polyribosomes) and catabolic (lysosomes, autophagosomes, multivesicular structures, and lipofuscin formations) systems in all cells. Pyramidal and mossy neurons die mainly by the necrotic pathway. The death of granular cells occurred through both apoptosis and necrosis. The most vulnerable cells are mossy neurons located in the hilus. Activation of the endocannabinoid system induced by intracerebral injection of URB597, an inhibitor of degradation of endocannabinoid anandamide, protected the normal structure of the hippocampus and prevented neuronal damage and death induced by KA.


Subject(s)
Arachidonic Acids/metabolism , Endocannabinoids/metabolism , Excitatory Amino Acid Agonists/pharmacology , Kainic Acid/pharmacology , Nerve Degeneration/pathology , Polyunsaturated Alkamides/metabolism , Pyramidal Cells/drug effects , Status Epilepticus/pathology , Animals , Autophagosomes/drug effects , Autophagosomes/metabolism , Autophagosomes/ultrastructure , Benzamides/pharmacology , CA3 Region, Hippocampal/drug effects , CA3 Region, Hippocampal/metabolism , CA3 Region, Hippocampal/pathology , Carbamates/pharmacology , Dentate Gyrus/drug effects , Dentate Gyrus/metabolism , Dentate Gyrus/pathology , Endoplasmic Reticulum/drug effects , Endoplasmic Reticulum/metabolism , Endoplasmic Reticulum/ultrastructure , Golgi Apparatus/drug effects , Golgi Apparatus/metabolism , Golgi Apparatus/ultrastructure , Lysosomes/drug effects , Lysosomes/metabolism , Lysosomes/ultrastructure , Male , Microscopy, Electron , Necrosis/metabolism , Necrosis/pathology , Nerve Degeneration/chemically induced , Nerve Degeneration/metabolism , Pyramidal Cells/metabolism , Pyramidal Cells/pathology , Rats , Rats, Wistar , Status Epilepticus/chemically induced , Status Epilepticus/metabolism
3.
Tsitologiia ; 56(12): 919-25, 2014.
Article in Russian | MEDLINE | ID: mdl-25929133

ABSTRACT

Comparison between results of different ways of application of excitotoxin (kainic acid, KA), intrahippocampal (0.2 µg/µl) and intraventricular (0.6 µg/µl), was carried out in the course of investigations of the prolonged action of KA on the morphological state of various fields in dorsal hippocampus. Light microscopy with Cresyl Violet staining and fluorescent microscopy with staining by fluoro-jade B were used in our researches. The results revealed that KA, being injected intrahippocampally at a dose, which does not result in animal epileptization, caused obvious degenerative phenomena in hippocampus. Two weeks after KA injection the layers of pyramid cells in the fields CA3 and CA4 were absent, and in four weeks, degenerative changes and cell lysis were spread on the CA1 field as well. Four weeks after KA intraventricular administration in rats with epileptic status the damages of various levels were observed in hippocampus, from partial injuries of pyramid neurons in the fields CA3 and CA4 up to full loss of layers of pyramids in the fields CA1, CA3 and CA4. In both ways of KA injection, in the CA2 field the layer of cells mainly remained undamaged what indicates a special role of this field. After a single-time KA administration the both ways of injection led to the long-term damages of a neural tissue, possibly, of a general character, but differing in rates of neuron reactions in different fields to the damaging factor. An explanation of the prolonged action of KA excitotoxicity might be in the activation of GluR6-containing kainate receptors in pyramid neurons in CA3 field which brings to chronic character in single-time KA action and promotes the destruction of the remaining neurons by necrotic way while at the initial stage of KA influence the neurons perish by apoptotic way.


Subject(s)
Cerebral Ventricles/pathology , Epilepsy/pathology , Hippocampus/pathology , Neurons/pathology , Animals , Apoptosis/drug effects , Benzoxazines , Cerebral Ventricles/drug effects , Cerebral Ventricles/metabolism , Epilepsy/chemically induced , Epilepsy/metabolism , Fluoresceins , Hippocampus/drug effects , Hippocampus/metabolism , Injections, Intraventricular , Kainic Acid/administration & dosage , Male , Microscopy, Fluorescence , Neurons/drug effects , Neurons/metabolism , Organ Specificity , Rats , Rats, Wistar , Receptors, Kainic Acid/metabolism , GluK2 Kainate Receptor
4.
Bull Exp Biol Med ; 155(6): 805-8090, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24288771

ABSTRACT

We studied the possibility of conditioning of food-procuring response in animals after impairment of the dorsal hippocampal region with kainic acid. Histological studies of brain sections showed that the greater part of dorsal hippocampal CA3 pyramidal neurons were lyzed in 2 weeks after kainic acid microinjection into the hippocampus. Morphological signs of necrosis were found in CA2 and CA4 neurons at the interface with CA3 field. Preinjection of anti-inflammatory cytokine IL-10 virtually did not prevent neuronal death. Damage to the hippocampus impaired learning of experimental animals and they required more attempts for reliable performance of the skill than the controls. Short-term memory of experimental rats was retained, which was proven by the results of single-day training. It was hypothesized that memory dysfunctions in animals after damage to the dorsal hippocampal CA3 field and to the hippocampus in general are determined by impaired transition of short-term into long-term memory.


Subject(s)
CA3 Region, Hippocampal/pathology , Memory Disorders/pathology , Animals , Cell Death , Feeding Behavior , Kainic Acid , Male , Memory Disorders/chemically induced , Pyramidal Cells/physiology , Rats , Rats, Wistar
5.
J Nanosci Nanotechnol ; 12(1): 119-26, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22523954

ABSTRACT

The dynamics of the state of hippocampal pyramidal neurons after intrahippocampal microinjections of (1) amyloid-beta25-35 (1.6 nmol/1 microl), (2) an aqueous molecule-colloidal solution of C60 (0.46 nmol/1 microl) and (3) an aqueous molecule-colloidal solution of C60 before amyloid-beta25-35 administration were analysed in rats. This model allowed us to study the role of amyloid-beta25-35 in the pathogenesis of Alzheimer's disease and to test anti-amyloid substances. Methods of fluorescent (acridine orange) and brightfield (cresyl violet and immunohistochemistry) microscopy were used. Acridine orange staining indicated changes in protein synthesis intensity due to alterations in the rRNA state of neuron ribosomes. One day after administration of amyloid-beta25-35, the intensity of protein synthesis in the population of morphologically intact cells decreased by 45%. By day 14, degeneration occurred in the majority of pyramidal cells, and amyloid-beta25-35 deposits were observed in the neuronal cytoplasm. In necrotic cells, acridine orange staining of the cytoplasm was drastically increased as a result of RNA degradation rather than due to an increase in protein synthesis. Because amyloid-beta25-35 administration provoked oxidative stress, we assumed that an aqueous molecule-colloidal solution of C60 administered before amyloid-beta25-35 prevented protein synthesis changes on day 1, while acting as an antioxidant, and by day 14 it inhibited neurodegeneration and amyloid-beta25-35 accumulation. Based on the data that an aqueous molecule-colloidal solution of C60 prevented amyloid-beta25-35 aggregation in in vitro experiments and based on our present evidence on the antitoxicity of an aqueous molecule-colloidal solution of C60, we suggest that functionalised C60 prevents/diminishes amyloid-beta25-35 aggregation in vivo as well. Thus, an aqueous molecule-colloidal solution of C60 administered at a low concentration before amyloid-beta2-35, prevented disturbances in protein synthesis, neurodegeneration and formation amyloid-beta25-35 deposits in hippocampal pyramidal neurons in vivo. This evidence gives promise that functionalised C60 can be used to develop anti-amyloid drugs combining antioxidant and anti-aggregative properties.


Subject(s)
Alzheimer Disease/pathology , Alzheimer Disease/prevention & control , Fullerenes/therapeutic use , Hippocampus/drug effects , Hippocampus/pathology , Alzheimer Disease/chemically induced , Amyloid beta-Peptides , Animals , Male , Microinjections , Neuroprotective Agents/administration & dosage , Peptide Fragments , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...